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The Importance of Venous Thromboembolism Management in the Oncology Population
Maura Price MSN, RN, OCN
Lehigh Valley Health Network, Allentown, Pennsylvania

SIGNIFICANCE &
BACKGROUND
•	Venous thromboembolism (VTE) is defined as
the development of a thrombus in the form of
a deep vein thrombosis (DVT), a pulmonary
embolism (PE), or a combination thereof
(McCance et al., 2010).
•	Due to the hypercoagulable state that occurs
with malignancy, oncology patients are 4-7
times more likely to develop VTE than the
general population
•	VTE coupled with thrombocytopenia, a
common toxicity experienced by patients
undergoing chemotherapy or radiation, can
make VTE management challenging
•	Risks of anticoagulant administration versus
anticoagulant holds during thrombocytopenia
must be considered to ensure patient safety

INTERVENTIONS
•	A literature search was
completed
•	National guidelines for VTE
management were reviewed
and compared
•	Guidelines were presented
to Lehigh Valley Health
Network’s (LVHN) Cancer
Committee
•	Standard parameter for
anticoagulant holds in the
thrombocytopenic oncology
patient was established
			−	
Unless contraindicated,
anticoagulants can be safely
administered to oncology
patients with a platelet
count of 50,000/ml or
higher

DISCUSSION

Comparison of Risk Assessment Tools
Assessment Tool

Population Validated In

Caprini Risk Assessment Model (RAM)

•	Surgical patients
• Gynecologic oncology patients

			 −	Decreased morbidity and mortality

Padua Risk Assessment Model (RAM)

•	Hospitalized medical patients

			 −	Reduced costs associated with VTE

Oncology
specific

Multiple Myeloma Risk Assessment Model (RAM)
(Thalidomide, Lenalidomide, Pomalidomide)

•

Oncology
specific

Khorana Predictive Model for ChemotherapyAssociated VTE

•	Surgical patients

Multiple Myeloma patients

Comparison of Guidelines & Current Recommendations
NCCN

MD Anderson

ASCO

MSKCC

ESMO

*Platelets
<25,000/ml

Platelets
<50,000/ml

Relative
Anaticoagulation
contraindications

Platelets
<50,000/ml

Platelets
<50,000/ml

Platelets
<50,000/ml

Cerebral
hemorrhage,
hemorrhage
in eye or vital
organs, hgb
drop of 2gm/
dL in 24 hours

Platelets
<20,000/ml

Absolute
contraindications

Active
bleeding2+ units
transfused
in 24 hours

To fill a gap in knowledge regarding proper
anticoagulant dosing and administration in the
thrombocytopenic oncology patient

			 −	Positively impact quality of life and reduce
chances of future VTE recurrence
			 −	Decrease the overall incidence of VTE in the
oncology population

Soff, 2013; NCCN,m 2016, Lyman et al., 2015; Mandala, Falanga & Roila, 2011.

EVALUATION
PURPOSE

•	Proper VTE management in the oncology
population can lead to:

•	Education on VTE management in the oncology population was assigned to
inpatient oncology nurses via LVHN’s online learning system
•	Nurses have voiced their appreciation for the education, review of guidelines, and
establishment of a standard parameter for anticoagulant holds
•	The education has led to decreased confusion over when to administer versus hold
anticoagulants during thrombocytopenia

•	Assessment and evaluation of VTE risk in
oncology patients is essential
•	Plans to implement a validated VTE risk
assessment tool into EPIC are underway at
LVHN
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